Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2073105rdf:typepubmed:Citationlld:pubmed
pubmed-article:2073105lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:2073105lifeskim:mentionsumls-concept:C0021270lld:lifeskim
pubmed-article:2073105lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:2073105lifeskim:mentionsumls-concept:C0053882lld:lifeskim
pubmed-article:2073105pubmed:issue11lld:pubmed
pubmed-article:2073105pubmed:dateCreated1991-4-8lld:pubmed
pubmed-article:2073105pubmed:abstractTextTwenty pediatric patients (ages, between 8 months and 8 years) received a single oral dose of cefprozil at levels of 15 and 30 mg/kg of body weight. Cefprozil consists of cis (BMY-28100) and trans (BMY-28167) isomers in an approximately 90:10 ratio. Six plasma samples were collected from each pediatric patient and assayed for drug concentrations. As measured by a microbiological assay, peak concentrations of 11.16 and 15.93 micrograms of cefprozil per ml occurred at 1 h for patients who received the 15- and 30-mg/kg doses, respectively. The respective mean half-lives of cefprozil were 1.77 and 2.14 h, and the respective mean areas under the curve were 28.05 and 45.28 micrograms.h/ml for patients who received the 15- and 30-mg/kg doses. When measured by a high-pressure liquid chromatography method, peak concentrations of 12.09 and 18.04 micrograms of the cis isomer per ml were obtained at 1 h, with mean half-lives of 1.63 and 2.06 h and mean areas under the curve of 30.48 and 49.34 micrograms.h/ml in patients who received the 15- and 30-mg/kg doses, respectively. For the trans isomer, peak concentrations of 1.16 and 1.63 micrograms/ml occurred at 1 h, respectively, with mean half-lives of 1.61 and 1.65 h and mean areas under the curve of 2.89 and 4.34 micrograms.h/ml in patients who received the 15- and 30-mg/kg doses, respectively.lld:pubmed
pubmed-article:2073105pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2073105pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2073105pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2073105pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2073105pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2073105pubmed:languageenglld:pubmed
pubmed-article:2073105pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2073105pubmed:citationSubsetIMlld:pubmed
pubmed-article:2073105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2073105pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2073105pubmed:statusMEDLINElld:pubmed
pubmed-article:2073105pubmed:monthNovlld:pubmed
pubmed-article:2073105pubmed:issn0066-4804lld:pubmed
pubmed-article:2073105pubmed:authorpubmed-author:NelsonJJlld:pubmed
pubmed-article:2073105pubmed:authorpubmed-author:SheltonSSlld:pubmed
pubmed-article:2073105pubmed:authorpubmed-author:ShyuW CWClld:pubmed
pubmed-article:2073105pubmed:authorpubmed-author:Sáez-LlorensX...lld:pubmed
pubmed-article:2073105pubmed:authorpubmed-author:KumieszHHlld:pubmed
pubmed-article:2073105pubmed:issnTypePrintlld:pubmed
pubmed-article:2073105pubmed:volume34lld:pubmed
pubmed-article:2073105pubmed:ownerNLMlld:pubmed
pubmed-article:2073105pubmed:authorsCompleteYlld:pubmed
pubmed-article:2073105pubmed:pagination2152-5lld:pubmed
pubmed-article:2073105pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:meshHeadingpubmed-meshheading:2073105-...lld:pubmed
pubmed-article:2073105pubmed:year1990lld:pubmed
pubmed-article:2073105pubmed:articleTitlePharmacokinetics of cefprozil in infants and children.lld:pubmed
pubmed-article:2073105pubmed:affiliationDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75235.lld:pubmed
pubmed-article:2073105pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2073105pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2073105pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2073105pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2073105lld:pubmed